#21-1344 Summer Street
Halifax, NS B3H 0A8
Full Time Employees: 8
|Dr. Armand Balboni J.D., M.D., Ph.D.||CEO & Director||284.11k||N/A||1966|
|Dr. Yoav Golan M.S., M.D., MS||Chief Medical Officer||252.47k||N/A||1962|
|Dr. Donald D. Cilla Jr., M.B.A., Pharm.D., Pharmd||Chief Devel. Officer||317.53k||N/A||N/A|
|Mr. Kenneth G. Howling||Acting Chief Financial Officer||N/A||N/A||N/A|
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Appili Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.